:quality(80)/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
Fresenius SE Aims to Improve Its Profitability
Fresenius SE’s prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and inorganic means.
Fresenius SE & Co KGaA FRE
Bulls Say, Bears Say
Bulls
Underlying demographic trends and international expansion opportunities should keep Fresenius’ dialysis services and related medical product growth in positive territory as the pandemic recedes.
Bears
Until the US achieves universal affordable coverage, policy risks around reimbursement for dialysis services may continue to add risk to the story.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FRE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €31.86
- Day Range
- €31.59–32.06
- 52-Week Range
- €23.93–32.06
- Bid/Ask
- €31.94 / €31.96
- Market Cap
- €17.94 Bil
- Volume/Avg
- 913,229 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 7.03
- Price/Sales
- 0.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- Large Value
- Total Number of Employees
- 190,863
- Website
- https://www.fresenius.com
Competitors
Valuation
|
Metric
|
FRE
|
DVA
|
ICUI
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.03 | 14.97 | 21.41 |
Price/Book Value | 0.92 | 13.01 | 1.51 |
Price/Sales | 0.66 | 1.03 | 1.37 |
Price/Cash Flow | 15.29 | 6.40 | 11.35 |
Price/Earnings
FRE
DVA
ICUI
Financial Strength
|
Metric
|
FRE
|
DVA
|
ICUI
|
|---|---|---|---|
Quick Ratio | 0.60 | 1.30 | 0.92 |
Current Ratio | 1.35 | 1.43 | 2.61 |
Interest Coverage | 2.85 | 4.36 | −0.05 |
Quick Ratio
FRE
DVA
ICUI
Profitability
|
Metric
|
FRE
|
DVA
|
ICUI
|
|---|---|---|---|
Return on Assets (Normalized) | 2.43% | 6.99% | 3.32% |
Return on Equity (Normalized) | 7.80% | 118.17% | 6.94% |
Return on Invested Capital (Normalized) | 4.23% | 10.75% | 5.84% |
Return on Assets
FRE
DVA
ICUI
Medical Care Facilities Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| HCA Healthcare Inc
HCA
| Vxyhcjg | Wlwjm | $92.9 Bil | |||
| Fresenius SE & Co KGaA ADR
FSNUY
| — | Nhzqp | $19.5 Bil | |||
| Fresenius SE & Co KGaA
FSNUF
| — | Wywtwk | $19.5 Bil | |||
| Tenet Healthcare Corp
THC
| Zzxtmccp | Zsbg | $14.8 Bil | |||
| Universal Health Services Inc Class B
UHS
| — | Mnpqkt | $14.3 Bil | |||
| DaVita Inc
DVA
| Qkkrvtpr | Cllxcz | $12.1 Bil | |||
| Fresenius Medical Care AG
FMCQF
| — | Whqs | $11.8 Bil | |||
| Fresenius Medical Care AG ADR
FMS
| Ltlv | Tjnrl | $11.8 Bil | |||
| Bangkok Dusit Medical Services PCL Shs Foreign Registered
BDULF
| — | Twbyfq | $11.6 Bil | |||
| AMN Healthcare Services Inc
AMN
| Yvxvbkk | Dvjpvl | $2.4 Bil |